WntResearch today announces that the last patient, in their on-going clinical phase 1 study with Foxy-5, has completed treatment at the last dose level (dose level 8) according to the protocol. As the Foxy-5 phase 1 study thereby is closed, data will be analysed and a summary report will be developed and presented during Q4. Some patients will continue their treatment for as long as their treating physician finds it appropriate.

Nils Brünner, CEO says, ”We are very pleased that we now have closed the Foxy-5 phase 1 study and look forward to explore the data and present it in a summary report as soon as possible. We also want to express our sincere gratitude to all patients who voluntarily participated, the treating physicians and nurses and the study team from Smerud for enabling the study. It truly has been an example of strong effort and good cooperation, which we hope will continue in the upcoming Phase 1b study. Finally, I also want to thank all our faithful stock owners who have made it all possible”.

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.